Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
The Mesothelioma Applied Research Foundation is excited to announce its latest research grant recipients, awarding a total of $300,000. This brings the Foundation’s total funding
At the Mesothelioma Applied Research Foundation, we are guided by the three core pillars that define our purpose: funding groundbreaking research, providing essential treatment support
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
